# US 2026/0062743 A1 · Detection of minimal residual disease from surgical drain fluid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062743 A1
- Document ID: US20260062743A1
- Status: Published application
- Kind: A1
- Application number: 19/313,338
- Filed: 2025-08-28
- Published: 2026-03-05
- Earliest claimed: 2024-08-28
- Assignees: Droplet Biosciences, Inc.
- Applicants: Droplet Biosciences, Inc.
- Inventors: Zhuosheng Gu; Wendy Winckler Adamovich
- Web page: https://patentgrep.com/patent/US20260062743A1

## CPC

- C12Q 1/6869: Methods for sequencing
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides methods for detecting and predicting minimal residual disease in a subject who has undergone tumor resection surgery. Methods of the invention utilize a personalized cutoff for determining the likelihood for MRD.

## Claims

### Claim 1

A method for establishing a personalized cutoff of minimal residual disease, the method comprising:
determining a depth of coverage of one or more mutations suspected to be present in a liquid biopsy sample obtained from a cancer patient;
sequencing nucleic acid in the sample at the determined depth of coverage to determine a number of a somatic mutation in the sample; and
establishing a personalized cutoff for the cancer patient based upon the number of somatic mutations and depth of coverage,
wherein subsequent results above the personalized cutoff indicate a recurrence of cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cutoff is determined as a product of an inverse of the number of somatic mutations and the depth of coverage.

### Claim 3 (depends on 1)

The method of claim 1, wherein the liquid biopsy sample is drain fluid from a surgical intervention.

### Claim 4 (depends on 3)

The method of claim 3, wherein the surgical drain fluid is obtained via a drain inserted during surgery.

### Claim 5 (depends on 3)

The method of claim 3, wherein the surgical drain fluid is obtained by irrigation during a surgical intervention.

### Claim 6 (depends on 3)

The method of claim 3, wherein the subsequent sample is collected post-surgery.

### Claim 7 (depends on 1)

The method of claim 1, wherein the nucleic acid is ctDNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is head and neck squamous cell carcinoma.

### Claim 9 (depends on 1)

The method of claim 1, further comprising selecting a therapeutic based on the personalized cutoff.

### Claim 10 (depends on 9)

The method of claim 9, further comprising administering the selected therapeutic to the patient.

### Claim 11 (depends on 1)

The method of claim 1, further comprising:
administering a therapeutic to the cancer patient after establishing a personalized cutoff;
determining a number of mutations present in a subsequent sample after administering the therapeutic; and
comparing the number of mutations to the personalized cutoff to evaluate the efficacy of the therapeutic.
